1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU
Newly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit First predictive...
Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings
Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending...
NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC) Marks third NCCN guideline recommendation on ctDNA-MRD testing, following...
Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs